Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 21, 2025
Finance
Antiviral, oncology company Genuine plots Hong Kong listing: Public Equity Report
Plus: Xtalpi, Solid and Arcus all raise cash
BioCentury | Mar 1, 2024
Finance
Venture report: Orbis, Curve leap into launches
Plus new rounds for Kenai, BlossomHill and more
BioCentury | Dec 16, 2023
Finance
Dec. 15 Quick Takes: Pfizer, Nona in ADC deal
Plus: FDA approves Padcev/Keytruda for 1L advanced urothelial cancer, obesity play Fractyl files for IPO and updates from Merck, Syndax, AC Immune, BMS
BioCentury | Aug 19, 2023
Regulation
Aug. 18 Quick Takes: FDA approvals for Regeneron, Neurocrine
Plus: Priority review for full approval of Calliditas’ Tarpeyo and updates from Astellas-Iveric, Merck, Arch newco TFC
BioCentury | Apr 1, 2022
Distillery Therapeutics
Blocking the PAI1/HIF2A axis for diabetic retinopathy
BioCentury | Dec 23, 2021
Product Development
First-in-class drugs fill FDA’s 2021 class of new approvals
Products against new targets accounted for nearly one third of NMEs, and fewer of them were for cancer than you might think
BioCentury | Nov 19, 2021
Deals
Momentum for TIGIT, adenosine with Gilead’s grab of Arcus options
While disclosed data remain limited, Gilead highlights potential for combos
Items per page:
1 - 10 of 49